Wells Fargo Downgrades Perrigo Co. (PRGO) to Market Perform

It's Too Early To Buy Perrigo (PRGO) - RBC

RBC Capital analyst, Randall Stanicky, cut his target on Perrigo Co. (NYSE: PRGO) to $109 from $140 as the estimate cuts overshadow even the loss of a CEO. No change to Sector Perform rating.

The departure of CEO Joe Papa to join VRX wasn't... More

Stifel Downgrades Perrigo Co. (PRGO) to Hold

Stifel downgraded Perrigo Co. (NYSE: PRGO) from Buy to Hold.

For an analyst ratings summary and ratings history on Perrigo Co. click here. For more ratings news on Perrigo Co. click here.

Shares of Perrigo Co. closed at $99.40 yesterday.

Jefferies Downgrades Perrigo Co. (PRGO) to Hold

Jefferies downgraded Perrigo Co. (NYSE: PRGO) from Buy to Hold with a price target of $112.00 (from $163.00).

Analyst David Steinberg commented, "PRGO confirmed that long-time CEO Joe Papa was departing & veteran John Hendrickson was graduating to the top spot. Time will... More

BofA/Merrill Lynch Downgrades Perrigo Co. (PRGO) to Underperform

BofA/Merrill Lynch downgraded Perrigo Co. (NYSE: PRGO) from Buy to Underperform.

For an analyst ratings summary and ratings history on Perrigo Co. click here. For more ratings news on Perrigo Co. click here.

Shares of Perrigo Co. closed at $121.35 yesterday.

BTIG Downgrades Perrigo Co. (PRGO) to Neutral

BTIG downgraded Perrigo Co. (NYSE: PRGO) from Buy to Neutral and removed its price target. Analyst Timothy Chiang said the departure of Joe Papa creates "significant uncertainty."

"Clearly, his resignation is unexpected and sends a negative ripple effect through the Co. While we... More

Perrigo (PRGO) Bears Case Suggests $82, But RBC Doesn't See Shares Going That Low

RBC Capital analyst Randall Stanicky weighed in on Perrigo Co. (NYSE: PRGO) with shares down 15% on news CEO Joe Papa is leaving for Valeant and lowered guidance from the company.

"The bottom line is this - despite the negative news PRGO is still a good business but one with near-term challenges and that we think can be bought lower," he commented. "There is clearly some short covering in the name today as debate around where the stock settles has been high."

The analyst offers for four follow-up thoughts:

Is... More

Perrigo (PRGO) Takeover Rumors Flare Up Amid Sell-Off on Papa News

Given weakness in Perrigo (NYSE: PRGO) amid the Joe Papa news and lowered guidance, takeover chatter can be heard reverberating around Wall Street.

As recently as November 2015 , Perrigo recommend investors reject the unsolicited takeover offer from Mylan NV (NASDAQ:... More

Valeant Pharma (VRX) Appoints Joseph Papa as CEO

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that its Board of Directors has named Joseph C. Papa to become Valeant's Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. Mr. Papa will join Valeant from Perrigo Company plc, a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as Chairman and Chief Executive Officer. Mr. Papa, who will also join Valeant's Board of Directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a... More

Perrigo (PRGO) Names John Hendrickson as CEO; Joe Papa Heads to Valeant (VRX)

Perrigo Company plc (NYSE: PRGO) announced the appointment of John T. Hendrickson as Chief Executive Officer, effective immediately, following the resignation and departure of Joseph C. Papa, who is expected to head to Valeant Pharma (NYSE: VRX).

Perrigo Chairman Laurie Brlas commented, "Aligned with our succession planning process, the Board of Directors has elevated John to Chief Executive Officer from President, where he led global operations and had responsibility for almost 70% of our employee base. John is an exceptional leader who is passionate about our mission,... More

Valeant names Papa CEO after he resigns from Perrigo

(Reuters) - Former Perrigo Co Plc (NYSE: PRGO) head Joseph Papa was named Chief Executive Officer at Valeant Pharmaceuticals International (NYSE: VRX) on Monday, a role in which investors said he should focus on returning the company to growth.

Papa will replace CEO Michael Pearson, whose years of frenzied dealmaking fueled double-digit profit increases at Valeant until scrutiny of its controversial relationship with a specialty pharmacy and history of sharp drug price increases hit its shares and sales last fall.

Shares of Laval, Quebec-based Valeant... More

Valeant Pharma (VRX) on Watch as Perrigo said to Name New CEO

Valeant Pharma (NYSE: VRX) on watch as Perrigo (NYSE: PRGO) said to name John Hendrickson CEO - Reuters

Last week reports surfaced that Valeant would name Perrigo's Joe Papa as its new CEO.

Perrigo (PRGO) said to name Jon Hendrickson as CEO - Reuters

Perrigo (NYSE: PRGO) said to name Jon Hendrickson as CEO, according to Reuters.

Perrigo (PRGO) said to name John Hendrickson CEO - Reuters

Perrigo (NYSE: PRGO) said to name John Hendrickson CEO - Reuters